Print Email this page Publications

The Patient Protection and Affordable Care Act (PPACA) recently passed by Congress contains two sections that establish new economic subsidies for companies engaged in research for new methods of diagnosis and treatment of human disease, the Qualifying Therapeutic Discovery Project Credit and the Cures Acceleration Network grant program. Because companies in this field tend to have a constant and pressing need for additional funding, competition for these credits and grants is likely to be intense.

Pryor Cashman Partner Stephen M. Goodman, a member of the firm’s Life Sciences practice, has prepared a brief summary of these two program for those persons who may wish to pursue these opportunities. To read the update, entitled Healthcare Reform – Research Stimulus Provisions, please click here.